Genprex, Inc. (GNPX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Genprex, Inc. is a clinical-stage gene therapy company focused on oncology (Reqorsa) and diabetes (GPX-002) treatments. This report covers the quarterly period ended June 30, 2024. The company is a non-accelerated filer and a smaller reporting company. Notably, the company's former President, CEO, and Chairman, Rodney Varner, passed away on May 7, 2024. Ryan M. Confer currently serves as both CEO and CFO.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(6,495,845) | $(7,980,193) | $(12,464,714) | $(17,182,967) |
| Net Loss Per Share (Basic/Diluted) | $(3.00) | $(6.14) | $(6.59) | $(13.55) |
| Research & Development Expense | $1,666,522 | $3,976,917 | $4,940,902 | $9,287,065 |
| General & Administrative Expense | $4,849,472 | $4,057,197 | $7,569,140 | $8,007,587 |
| Cash and Cash Equivalents (End of Period) | $2,459,024 | $9,955,684 | $2,459,024 | $9,955,684 |
| Net Cash Used in Operating Activities | N/A | N/A | $(11,093,733) | $(15,039,538) |
| Net Cash Provided by Financing Activities | N/A | N/A | $6,813,961 | $4,080,780 |
Note: The company has no revenue. Operating expenses include a one-time non-cash charge of approximately $790,000 in Q2 2024 due to a change in accounting policy regarding intellectual property.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by 19% in Q2 and 27% YTD compared to the prior year periods. This was driven by a 58% reduction in R&D expenses (Q2) and a 47% reduction YTD, primarily due to switching Contract Development and Manufacturing Organizations (CDMOs) and reducing headcount (R&D staff reduced from 18 to 13).
- Accounting Change: The company changed its accounting principle for intellectual property costs, expensing $790,466 of previously capitalized costs in Q2 2024. This contributed to a 20% increase in G&A expenses for Q2 compared to Q2 2023, despite other cost-cutting measures.
- Liquidity: Cash balances decreased from $6.7 million at year-end 2023 to $2.5 million at June 30, 2024. The company raised approximately $6.8 million in financing activities YTD 2024, including a registered direct offering in March 2024.
- Capital Structure: A 1-for-40 reverse stock split was completed on February 2, 2024. As of June 30, 2024, there were 2,555,735 shares of common stock outstanding.
Guidance, Outlook, and Risks
- Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. Current cash is estimated to fund operations only through September 2024. Additional financing is required to continue clinical trials.
- Clinical Progress:
- Acclaim-3 (SCLC): Phase 1 dose escalation is ongoing. The first patient showed a partial remission (30% tumor decrease) after two cycles, though disease progression was noted at three months. Phase 2 expansion expected to start in H2 2024.
- Acclaim-1 (NSCLC): Phase 2a expansion is ongoing. Enrollment is limited to patients who received only prior Tagrisso treatment. Interim analysis expected in H1 2025.
- Acclaim-2 (NSCLC): Enrollment ceased to prioritize resources for Acclaim-1 and Acclaim-3.
- Diabetes (GPX-002): Preclinical studies continue. FDA guidance for IND-enabling studies is anticipated in H1 2025.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and insufficient accounting personnel depth. Remediation efforts are underway.
- CDMO Termination: A development services agreement with a CDMO was terminated in June 2024, with the CDMO agreeing to return $1.3 million to the company.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before September 2024 to avoid operational disruption.
- Clinical Data: Monitor upcoming data readouts from the Acclaim-3 and Acclaim-1 trials, specifically regarding the durability of the partial remission observed in Acclaim-3.
- Internal Controls: Review future filings for confirmation that material weaknesses in financial reporting have been remediated.
- Dilution Risk: Assess the impact of outstanding warrants (2.76 million shares) and pre-funded warrants on future share count and dilution.
- Accounting Policy: Confirm that the one-time $790k IP expense is fully recognized and will not recur in future periods.